Hematopoietic Colony-Stimulating Factors (Csfs)

Hematopoietic Colony-Stimulating Factors (CSFs) are biologic agents used to stimulate the production of neutrophils and reduce the incidence of febrile neutropenia in patients undergoing cytotoxic chemotherapy. Their use has been shown to decrease hospitalization rates, treatment-related complications, and improve patient quality of life. Multiple CSFs are available, including filgrastim, pegfilgrastim, and tbo-filgrastim, as well as biosimilars. Several brands of short-acting colony-stimulating factors (CSFs) are available, including Neupogen® (filgrastim), Zarxio® (filgrastim-sndz), Nivestym® (filgrastim-aafi), Granix® (tbo-filgrastim), and Leukine® (sargramostim). There is no reliable evidence that any one short-acting CSF brand is superior to another for medically necessary indications. Long-acting granulocyte colony-stimulating factors (G-CSFs) include Neulasta® (pegfilgrastim), Neulasta Onpro® kit (pegfilgrastim), Nyvepria® (pegfilgrastim-apgf), Fulphila® (pegfilgrastim-jmdb), Udenyca® (pegfilgrastim-cbqv), and Ziextenzo® (pegfilgrastim-bmez). Evidence similarly shows no clinically meaningful differences in efficacy or safety between available pegfilgrastim products. <a id="